U.S. Industrial REITs Stock News

MGIC Investment (MTG) recently reported Q2 earnings with revenue roughly matching expectations and earnings per share above analyst estimates. Management highlighted a 14.5% return on equity, and the stock gained about 1.9% following the release. See our latest analysis for MGIC Investment. For context, MGIC Investment’s share price has a 90 day share price return of 19.33% and a year to date share price return of 6.72%, while the 1 year total shareholder return is 16.69% and the 5 year total...

In August 2026, Enact Holdings, Inc. reported second-quarter 2026 results showing revenue of US$317.31 million and net income of US$174.84 million, alongside basic and diluted earnings per share from continuing operations of US$1.25, all above the prior-year period. On the same day, the company reinforced its focus on capital returns by declaring a US$0.24 per-share dividend and completing a US$155.09 million buyback program that retired 3,684,091 shares, or 2.62% of its stock. We’ll now...

Multiple August announcements around MaxLinear (MXL) products for AI data centers and new client collaborations have put the stock back in focus. Investors are weighing how this broader portfolio could influence long term fundamentals. See our latest analysis for MaxLinear. The recent product launches for AI data centers and new client collaborations have arrived during a sharp move in MaxLinear’s share price, with a 7 day share price return of 23.85% and a year to date share price return of...

TechnipFMC plc recently announced it had secured a “significant” contract, valued between US$75 million and US$250 million, from Azule Energy to design and manufacture flexible flowlines, risers, and related equipment for the West Hub Tails extension of the Block 15/06 Agogo Integrated Development. This award, which will be booked into third-quarter 2026 inbound orders, highlights TechnipFMC’s role in consolidating West Hub production through the Agogo FPSO, reinforcing demand for its core...

In August 2026, Harrow, Inc. reported second-quarter revenue of US$70.66 million versus US$63.74 million a year earlier, swung to a net loss of US$17.27 million, and reiterated its 2026 revenue guidance of US$350 million to US$365 million. Just days earlier, Harrow agreed to acquire TYRVAYA nasal spray for up to US$100 million, aiming to broaden its dry eye disease franchise with a drop-free treatment that complements its existing VEVYE offering. Next, we’ll examine how reaffirmed 2026...

Agios Pharmaceuticals (AGIO) has drawn investor focus after recent trading left the stock at a last close of $33.63. With mixed return figures across different periods, the company’s rare disease portfolio is gaining fresh attention. See our latest analysis for Agios Pharmaceuticals. Over the past year, Agios Pharmaceuticals has combined a 23.73% year to date share price return with a 21.28% 90 day share price gain, yet the 1 year total shareholder return declined 10.20%. This suggests that...

Why Tarsus Pharmaceuticals stock is in focus after Q2 2026 Tarsus Pharmaceuticals (TARS) is back on investors radar after its Q2 2026 earnings report showed higher revenue, a smaller net loss, and a higher full year sales outlook for XDEMVY. See our latest analysis for Tarsus Pharmaceuticals. Tarsus Pharmaceuticals shares have reacted positively to the Q2 2026 update, with a 17.99% 1 month share price return and a 15.21% 3 month share price return, while the year to date share price is still...

With the clock ticking on potential 50% U.S. tariffs on Canadian goods, investors are watching domestic industrials in a new light. Companies with U.S. heavy operations and lower Canada revenue exposure could face a very different trade impact than cross border peers, for better or worse. This article walks through 3 stocks from that group and explains how the current tariff standoff might affect each one. The sample of stocks below is only a starting point, since the full screen surfaced 61...

Hamilton Lane’s August 4, 2026 report showed first‑quarter revenue of US$275.33 million and net income of US$80.46 million, with basic earnings per share from continuing operations of US$1.94, all higher than the same period a year earlier. At the same time, the company declared a quarterly dividend of US$0.60 per Class A share, lifting its full‑year dividend target by 11%, which underscores management’s confidence in current cash flows and capital‑return capacity. We’ll now examine how this...

On 4 August 2026, Medera Inc. announced a collaboration with IQVIA Inc. to combine IQVIA’s global clinical trial and commercialization capabilities with Medera’s Sardocor gene therapy programs and Novoheart’s engineered human cardiac tissue platform for drug discovery and safety testing. By pairing IQVIA’s regulatory and trial execution expertise with Medera’s human-based disease modelling technologies, the partnership underscores how IQVIA is embedding itself deeper into emerging areas like...

Klaviyo, Inc. reported past second-quarter 2026 results with revenue of US$370.58 million and a narrower net loss of US$8.85 million, while also issuing higher full-year revenue guidance and confirming third-quarter expectations. The company is pairing this improved financial profile with AI-focused expansion, acquiring Agency’s team and technology and appointing founder Elias Torres as Chief Product Officer to accelerate its agent product line. We’ll now examine how Klaviyo’s raised...

Aura Minerals (AUGO) just reported quarterly and half year results that show higher sales and a sharp swing to profit, while also reaffirming its 2026 production targets to give investors clearer visibility. See our latest analysis for Aura Minerals. The strong earnings release, dividend declaration and recent buyback have come alongside a sharp move in Aura Minerals' stock, with a 30 day share price return of 56.39% and a one year total shareholder return of 188.55% signalling strong...

Oil is back in the spotlight as Brent edges toward US$90, inflation worries return and war with Iran keeps traders on alert about global supply. At the same time, higher US Treasury yields are pressuring valuations while strong earnings keep stocks near record highs. This article walks through 3 large energy producers that screens suggest are most exposed to this mix of rising crude, rates and profit expectations. The 3 stocks below are just a starting sample, and the full screen surfaced 8...

The Chefs' Warehouse, Inc. previously began a refinancing process, marketing and later upsizing a new US$675 million term loan facility to refinance existing debt, redeem convertible notes, fund capital expenditures, and support general corporate purposes. This prospective refinancing could meaningfully reshape the company’s capital structure by consolidating borrowings into a single term loan while potentially extending maturities and increasing financial flexibility. We’ll now examine how...

Hagerty (HGTY) is back in focus after its Broad Arrow unit reported record results at The Quail Auction, along with raised full year revenue and earnings guidance that contrasted with mixed second quarter figures. See our latest analysis for Hagerty. Hagerty shares trade at US$12.86 after a slight 1-day decline in the share price return of 0.85%, although a 16.38% 90-day share price return and a 46.30% three-year total shareholder return suggest momentum has been building over time. If this...

Apple Hospitality REIT, Inc. recently reported its second-quarter 2026 results, with sales of US$365.17 million, revenue of US$402.55 million and net income of US$67.08 million, all higher than the same period a year earlier, and modestly improved earnings per share from continuing operations. Alongside these results, the company raised its full-year 2026 net income guidance by US$10 million at the midpoint and outlined US$85 million to US$95 million of capital investments focused on...

In August 2026, Cheniere Energy Partners, L.P. reported past second-quarter 2026 results showing revenue of US$2,583 million and net income of US$1,161 million, with basic earnings per share from continuing operations of US$2.14, all higher than the same period a year earlier. For the first half of 2026, the partnership’s revenue rose to US$6,183 million and net income to US$1,347 million, indicating stronger profitability and higher earnings per unit compared with the prior-year...

AI related stocks have surged into the spotlight again after the ECB warned that the current rally in US tech valuations is edging into territory linked with past bubbles. That creates both risk and opportunity for anyone with exposure to AI heavy benchmarks. This article walks through 3 large cap AI and semiconductor leaders from our screener that could be especially sensitive if a sharp AI revaluation occurs. The stocks covered below are just a starting sample from this theme. The full...

Crescent Energy recently raised its full-year 2026 production guidance, now targeting 327,000 to 335,000 barrels of oil equivalent per day, and confirmed a total quarterly dividend of US$0.12 per share with an ex-dividend date of August 17, 2026. This combination of higher expected output and a sustained dividend policy sharpens the focus on how Crescent balances growth with long-term payout support. We will now examine how the upgraded production guidance reshapes Crescent Energy’s...

In recent months, FedEx has pursued further automation with robotic loading systems and continued cost-cutting through facility closures and workforce reductions, aiming to improve network efficiency and cash generation. This combination of technology investment and restructuring highlights a tension between potential long-term productivity gains and the risk that aggressive cost measures could affect service quality and operational execution. Against this backdrop, we’ll explore how FedEx’s...

Revolution Medicines (RVMD) drew investor attention after announcing a multi part collaboration with BeOne Medicines. The deal covers joint clinical studies on RAS(ON) inhibitors and grants BeOne exclusive development and commercialization rights in select Asian markets. See our latest analysis for Revolution Medicines. The BeOne Medicines news lands at a time when Revolution Medicines has already seen strong share price momentum, including a 13.88% 1 month share price return and a year to...

In August 2026, Halozyme Therapeutics reported past second-quarter 2026 results showing revenue of US$481.00 million and net income of US$229.91 million, alongside higher earnings per share and the completion of share repurchases totaling 13,452,356 shares for US$750.00 million across two programs. The company also raised its 2026 total revenue guidance to a range of US$1.84 billion to US$1.91 billion, indicating management’s increased confidence after strong first-half performance and...

Recently, analysis of Q2 Holdings highlighted that its cloud-based digital banking platform is now facing slower average billings growth alongside elevated servicing costs. This shift, occurring despite the company remaining profitable, raises fresh questions about how efficiently Q2 can scale its business model over time. We’ll now examine how concerns over slowing billings growth could reshape Q2 Holdings’ broader investment narrative for investors. Find 53 companies with promising cash...

Albany International Corp. recently reported past second-quarter 2026 results showing higher sales of US$329.48 million and net income of US$17.41 million, alongside completing a US$173.36 million share repurchase program that retired 2,682,859 shares. The company also issued third-quarter 2026 revenue guidance of US$320 million to US$330 million, giving investors a clearer view of near-term operating momentum and capacity to generate earnings from continuing operations. With this...